RayzeBio Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ken Song
Chief executive officer
US$5.7m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | 3.6yrs |
| CEO ownership | 2.7% |
| Management average tenure | 2.5yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$65m |
| Jun 30 2023 | n/a | n/a | -US$70m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$6m | US$475k | -US$73m |
Compensation vs Market: Ken's total compensation ($USD5.72M) is about average for companies of similar size in the US market ($USD6.32M).
Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.
CEO
Ken Song (48 yo)
3.6yrs
Tenure
US$5,724,876
Compensation
Dr. Kenneth Song, also known as Ken, MD, serves as the President and Chief Executive Officer of RayzeBio, Inc. and has been its Director since July 2020. Dr. Song served as Chief Executive Officer and Pres...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$5.72m | 2.71% $ 101.4m | |
| Chief Financial Officer | 2.3yrs | US$1.94m | 0.13% $ 4.8m | |
| Chief Medical Officer | 2.6yrs | US$1.91m | 0.54% $ 20.2m | |
| Co-Founder | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Senior Vice President of Development & Operations | 3.2yrs | no data | no data | |
| Senior Vice President of Biology & Translational Medicine | 3.2yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 2.5yrs | no data | no data | |
| Senior Vice President of Chemistry Innovation | 2.5yrs | no data | no data | |
| Senior VP of Chemistry & Head of Discovery | 1.4yrs | no data | no data | |
| Senior Vice President of Finance | no data | no data | no data | |
| Vice President and Head of Regulatory & Quality | no data | no data | no data |
2.5yrs
Average Tenure
51yo
Average Age
Experienced Management: RYZB's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$5.72m | 2.71% $ 101.4m | |
| Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 2.4yrs | US$303.12k | no data | |
| Independent Director | 1.9yrs | US$841.18k | no data | |
| Independent Chairman of Board of Directors | 1.2yrs | US$2.36m | 0.61% $ 23.0m | |
| Independent Director | less than a year | no data | 0.19% $ 7.2m | |
| Director | 2.8yrs | US$270.40k | no data | |
| Director | less than a year | no data | no data |
1.7yrs
Average Tenure
50yo
Average Age
Experienced Board: RYZB's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/27 01:57 |
| End of Day Share Price | 2024/02/23 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RayzeBio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Yee | Jefferies LLC |
| Jessica Fye | J.P. Morgan |
| Robyn Kay Karnauskas | Truist Securities |